Financhill
Sell
20

EDAP Quote, Financials, Valuation and Earnings

Last price:
$2.30
Seasonality move :
35.05%
Day range:
$2.18 - $2.28
52-week range:
$2.14 - $8.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.19x
P/B ratio:
1.71x
Volume:
40.3K
Avg. volume:
171.6K
1-year change:
-56%
Market cap:
$81.6M
Revenue:
$65.4M
EPS (TTM):
-$0.63

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EDAP
Edap TMS SA
$17M -$0.17 -1.4% -21.79% --
ADAP
Adaptimmune Therapeutics PLC
$20.5M -$0.18 4199.24% -9.44% $3.50
AKTX
Akari Therapeutics PLC
-- -- -- -- --
CLLS
Cellectis SA
$9.1M -$0.24 3346.52% -69.12% --
DBVT
DBV Technologies SA
$1.1M -$1.77 -- -59.89% --
GNFT
Genfit SA
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EDAP
Edap TMS SA
$2.20 -- $81.6M -- $0.00 0% 1.19x
ADAP
Adaptimmune Therapeutics PLC
$0.60 $3.50 $154.8M -- $0.00 0% 0.85x
AKTX
Akari Therapeutics PLC
$0.97 -- $24M -- $0.00 0% --
CLLS
Cellectis SA
$1.61 -- $161.2M -- $0.00 0% 4.96x
DBVT
DBV Technologies SA
$3.19 -- $65.4M -- $0.00 0% --
GNFT
Genfit SA
$3.80 -- $189.6M 33.72x $0.00 0% 2.75x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EDAP
Edap TMS SA
8.17% -1.301 4.48% 1.42x
ADAP
Adaptimmune Therapeutics PLC
38.4% 5.180 20.51% 3.54x
AKTX
Akari Therapeutics PLC
-- 0.396 -- --
CLLS
Cellectis SA
26.36% 0.776 21.83% 1.74x
DBVT
DBV Technologies SA
-- -0.249 -- --
GNFT
Genfit SA
-- -0.225 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EDAP
Edap TMS SA
$5.7M -$6.4M -39.29% -42.5% -44.53% -$6.7M
ADAP
Adaptimmune Therapeutics PLC
-- -$14.7M -55.22% -67.8% -38.33% -$54.9M
AKTX
Akari Therapeutics PLC
-- -$1.9M -- -- -- -$1.5M
CLLS
Cellectis SA
-- -$10.8M -57.78% -79.78% -130.83% -$6.6M
DBVT
DBV Technologies SA
-- -$30.3M -- -- -- -$22.9M
GNFT
Genfit SA
-- -- -- -- -- --

Edap TMS SA vs. Competitors

  • Which has Higher Returns EDAP or ADAP?

    Adaptimmune Therapeutics PLC has a net margin of -48.85% compared to Edap TMS SA's net margin of -43.07%. Edap TMS SA's return on equity of -42.5% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    39.35% -$0.19 $51.9M
    ADAP
    Adaptimmune Therapeutics PLC
    -- -$0.06 $129.9M
  • What do Analysts Say About EDAP or ADAP?

    Edap TMS SA has a consensus price target of --, signalling upside risk potential of 384.85%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $3.50 which suggests that it could grow by 274.78%. Given that Edap TMS SA has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Edap TMS SA is more attractive than Adaptimmune Therapeutics PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    0 0 0
    ADAP
    Adaptimmune Therapeutics PLC
    4 2 0
  • Is EDAP or ADAP More Risky?

    Edap TMS SA has a beta of 0.329, which suggesting that the stock is 67.134% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.863%.

  • Which is a Better Dividend Stock EDAP or ADAP?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or ADAP?

    Edap TMS SA quarterly revenues are $14.4M, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. Edap TMS SA's net income of -$7M is higher than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, Edap TMS SA's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.19x versus 0.85x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    1.19x -- $14.4M -$7M
    ADAP
    Adaptimmune Therapeutics PLC
    0.85x -- $40.9M -$17.6M
  • Which has Higher Returns EDAP or AKTX?

    Akari Therapeutics PLC has a net margin of -48.85% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -42.5% beat Akari Therapeutics PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    39.35% -$0.19 $51.9M
    AKTX
    Akari Therapeutics PLC
    -- -$0.24 --
  • What do Analysts Say About EDAP or AKTX?

    Edap TMS SA has a consensus price target of --, signalling upside risk potential of 384.85%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 8147.42%. Given that Akari Therapeutics PLC has higher upside potential than Edap TMS SA, analysts believe Akari Therapeutics PLC is more attractive than Edap TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    0 0 0
    AKTX
    Akari Therapeutics PLC
    0 0 0
  • Is EDAP or AKTX More Risky?

    Edap TMS SA has a beta of 0.329, which suggesting that the stock is 67.134% less volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.791, suggesting its less volatile than the S&P 500 by 20.903%.

  • Which is a Better Dividend Stock EDAP or AKTX?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or AKTX?

    Edap TMS SA quarterly revenues are $14.4M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Edap TMS SA's net income of -$7M is lower than Akari Therapeutics PLC's net income of -$2.9M. Notably, Edap TMS SA's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.19x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    1.19x -- $14.4M -$7M
    AKTX
    Akari Therapeutics PLC
    -- -- -- -$2.9M
  • Which has Higher Returns EDAP or CLLS?

    Cellectis SA has a net margin of -48.85% compared to Edap TMS SA's net margin of -142.32%. Edap TMS SA's return on equity of -42.5% beat Cellectis SA's return on equity of -79.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    39.35% -$0.19 $51.9M
    CLLS
    Cellectis SA
    -- -$0.23 $175.7M
  • What do Analysts Say About EDAP or CLLS?

    Edap TMS SA has a consensus price target of --, signalling upside risk potential of 384.85%. On the other hand Cellectis SA has an analysts' consensus of -- which suggests that it could grow by 314.08%. Given that Edap TMS SA has higher upside potential than Cellectis SA, analysts believe Edap TMS SA is more attractive than Cellectis SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    0 0 0
    CLLS
    Cellectis SA
    0 0 0
  • Is EDAP or CLLS More Risky?

    Edap TMS SA has a beta of 0.329, which suggesting that the stock is 67.134% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.093, suggesting its more volatile than the S&P 500 by 209.338%.

  • Which is a Better Dividend Stock EDAP or CLLS?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or CLLS?

    Edap TMS SA quarterly revenues are $14.4M, which are smaller than Cellectis SA quarterly revenues of $16.2M. Edap TMS SA's net income of -$7M is higher than Cellectis SA's net income of -$23.1M. Notably, Edap TMS SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.19x versus 4.96x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    1.19x -- $14.4M -$7M
    CLLS
    Cellectis SA
    4.96x -- $16.2M -$23.1M
  • Which has Higher Returns EDAP or DBVT?

    DBV Technologies SA has a net margin of -48.85% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -42.5% beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    39.35% -$0.19 $51.9M
    DBVT
    DBV Technologies SA
    -- -$1.60 --
  • What do Analysts Say About EDAP or DBVT?

    Edap TMS SA has a consensus price target of --, signalling upside risk potential of 384.85%. On the other hand DBV Technologies SA has an analysts' consensus of -- which suggests that it could grow by 590.04%. Given that DBV Technologies SA has higher upside potential than Edap TMS SA, analysts believe DBV Technologies SA is more attractive than Edap TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    0 0 0
    DBVT
    DBV Technologies SA
    0 0 0
  • Is EDAP or DBVT More Risky?

    Edap TMS SA has a beta of 0.329, which suggesting that the stock is 67.134% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.828%.

  • Which is a Better Dividend Stock EDAP or DBVT?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or DBVT?

    Edap TMS SA quarterly revenues are $14.4M, which are larger than DBV Technologies SA quarterly revenues of --. Edap TMS SA's net income of -$7M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Edap TMS SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.19x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    1.19x -- $14.4M -$7M
    DBVT
    DBV Technologies SA
    -- -- -- -$30.4M
  • Which has Higher Returns EDAP or GNFT?

    Genfit SA has a net margin of -48.85% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -42.5% beat Genfit SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    39.35% -$0.19 $51.9M
    GNFT
    Genfit SA
    -- -- --
  • What do Analysts Say About EDAP or GNFT?

    Edap TMS SA has a consensus price target of --, signalling upside risk potential of 384.85%. On the other hand Genfit SA has an analysts' consensus of -- which suggests that it could grow by 170.55%. Given that Edap TMS SA has higher upside potential than Genfit SA, analysts believe Edap TMS SA is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    0 0 0
    GNFT
    Genfit SA
    0 0 0
  • Is EDAP or GNFT More Risky?

    Edap TMS SA has a beta of 0.329, which suggesting that the stock is 67.134% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.145, suggesting its more volatile than the S&P 500 by 14.458%.

  • Which is a Better Dividend Stock EDAP or GNFT?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or GNFT?

    Edap TMS SA quarterly revenues are $14.4M, which are larger than Genfit SA quarterly revenues of --. Edap TMS SA's net income of -$7M is higher than Genfit SA's net income of --. Notably, Edap TMS SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 33.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.19x versus 2.75x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    1.19x -- $14.4M -$7M
    GNFT
    Genfit SA
    2.75x 33.72x -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 5.73% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 7.2% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 4.6% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock